Newsroom

Cell and Gene Therapy Innovator Castle Creek Biosciences Appoints Matthew Gantz as President and Chief Executive Officer

Overview

Corporate Profile

Castle Creek Biosciences, Inc. is a privately held, clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. The company is using its proprietary fibroblast platform to develop dabocemagene autoficel (also known as D-Fi), an investigational, autologous fibroblast cell-based gene therapy that is designed to be administered intradermally to potentially treat the underlying cause of autosomal recessive and dominant dystrophic epidermolysis bullosa, or DEB. Castle Creek is also developing FCX-013, an investigational, autologous fibroblast cell-based gene therapy that is designed to be administered intradermally to potentially treat moderate to severe localized scleroderma. The company operates an in-house, commercial-scale facility located in Exton, Pennsylvania, which is designed to be current good manufacturing practices-compliant (cGMP). Castle Creek Biosciences is a portfolio company of Paragon Biosciences.

Investors